ALMS
ALUMIS INC.
NASDAQ · Healthcare · Biotechnology · US
$7.77
−0.64%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.86
From 52W high−74.36%
Volume6.38M
Market cap$1.01B
P/E (TTM)—
P/S (TTM)135.9x
Div yield—
Key dataSep 18, 2026
Open
$7.86
From 52W high
−74.36%
Volume
6.38M
Market cap
$1.01B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
19.1
MomentumView details →
1D Return
−0.64%
YTD Return
−22.54%
SummaryUpdated Jun 1, 2026
Alumis Inc. (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in South San Francisco, California. Originally incorporated as Esker Therapeutics, Inc., the company rebranded to Alumis Inc. in January 2022 before going public in February 2021. The company focuses on developing innovative medicines for autoimmune and inflammatory disorders, with its lead programs targeting a specific enzyme pathway called tyrosine kinase 2 (TYK2) that plays a crucial role in immune system regulation.
Similar companies
Latest newsMore news →
ALUMIS stock resumed trading and plunged 57% in premarket after a failed trial sale.19d agoAlumis announced that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus did not meet primary and secondary endpoints in the overall population, but showed robust responses in the IFNGS-high subgroup, supporting Phase 3 development in SLE.19d agoAlumis announced topline results from its ONWARD3 long-term extension study, showing envudeucitinib achieved high skin clearance rates in psoriasis patients.41d ago